<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article326</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/UPLIFT" style="display:block; margin-bottom:10px;">UPLIFT Original</a></li>
<h2><strong>UPLIFT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Tiotropium and Outcomes in Chronic Obstructive Pulmonary Disease". The New England Journal of Medicine. 2008. 359(15):1543-1554. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with chronic obstructive pulmonary disease (COPD), does long-term therapy with tiotropium improve clinical outcomes?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with COPD, therapy with tiotropium over a 4-year period improved lung function, quality of life, and exacerbations but did not significantly slow the rate of decline in FEV1.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the time of the study, guidelines did not specifically recommend the use of tiotropium for altering disease progression, though it may be used for symptomatic relief.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, placebo-controlled, parallel-group trial<br/>
- N=5,993 patients with moderate-to-very-severe COPD<br/>
- Tiotropium (n=2,987) vs. Placebo (n=3,006)<br/>
- Setting: 490 investigational centers in 37 countries<br/>
- Enrollment: January 2003 to March 2004<br/>
- Analysis: Intention-to-treat<br/>
- Follow-up: 4 years<br/>
- Primary outcome: Yearly rate of decline in mean FEV1 before and after bronchodilation from day 30 until completion of double-blind treatment<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Diagnosis of COPD<br/>
- Age ≥40 years<br/>
- Smoking history of ≥10 pack-years<br/>
- Postbronchodilator FEV1 ≤70% predicted and FEV1/FVC ratio ≤70% after bronchodilation<br/>
<br/>
Exclusion Criteria<br/>
- Asthma history<br/>
- COPD exacerbation or respiratory infection within 4 weeks before screening<br/>
- History of pulmonary resection<br/>
- Use of supplemental oxygen &gt;12 hours/day<br/>
- Coexisting illness impacting participation or results<br/>
<br/>
Baseline Characteristics<br/>
- Mean age: 65±8 years<br/>
- 75% male, 30% current smokers<br/>
- Mean postbronchodilator FEV1: 1.32±0.44 liters (48% predicted)<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Patients received either 18 μg of tiotropium or matching placebo once daily delivered through the HandiHaler inhalation device<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- No significant differences between groups in the rate of decline in the mean FEV1 before or after bronchodilation from day 30 to the end of the study-drug treatment<br/>
<br/>
Secondary Outcomes<br/>
- Tiotropium group maintained mean FEV1 and FVC improvements throughout the trial compared to placebo (P&lt;0.001)<br/>
- SGRQ scores were better in the tiotropium group throughout the 4-year period (P&lt;0.001)<br/>
- Delay in time to the first exacerbation and hospitalization for an exacerbation with tiotropium<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by Boehringer Ingelheim and Pfizer.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
